PRELUDE THERAPEUTICS INC Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
PRELUDE THERAPEUTICS INC (PRLD) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $109.00 thousand for the 3-month period ending 2024-03-31, per its 10-Q filed 2025-05-06.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2025-05-06
- PRELUDE THERAPEUTICS INC right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2024-03-31 was $109.00K.
- PRELUDE THERAPEUTICS INC right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2022-12-31 was $875.00K.
- PRELUDE THERAPEUTICS INC right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2022-09-30 was $0.00.
- PRELUDE THERAPEUTICS INC right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2022-06-30 was $0.00.
- PRELUDE THERAPEUTICS INC right-of-use asset obtained in exchange for operating lease liability for fiscal 2023 was $16.68M, a 825.12% increase from fiscal 2022.
- PRELUDE THERAPEUTICS INC right-of-use asset obtained in exchange for operating lease liability for fiscal 2022 was $1.80M, a 217.99% increase from fiscal 2021.
- PRELUDE THERAPEUTICS INC right-of-use asset obtained in exchange for operating lease liability for fiscal 2021 was $567.00K.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2024-03-31 | $109.00K 10-Q · filed 2025-05-06 | |||
| 2023-12-31 | $16.68M 10-K · filed 2025-03-10 | |||
| 2022-12-31 | $875.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | $875.00K derived: sum of 2 quarters · filed 2024-02-15 | $875.00K derived: sum of 3 quarters · filed 2024-02-15 | $1.80M 10-K · filed 2024-02-15 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-01 | $0.00 derived: sum of 2 quarters · filed 2023-11-01 | $928.00K 10-Q · filed 2023-11-01 | $928.00K derived: sum of 4 quarters · filed 2023-11-01 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $928.00K 10-Q · filed 2023-08-03 | $928.00K derived: sum of 3 quarters · filed 2023-08-03 | |
| 2022-03-31 | $928.00K 10-Q · filed 2023-05-08 | $928.00K derived: sum of 2 quarters · filed 2023-05-08 | ||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $567.00K 10-K · filed 2023-03-15 | ||
| 2021-09-30 | $567.00K 10-Q · filed 2022-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |